User login
Key clinical point: Abrocitinib monotherapy was associated with a rapid and profound relief in atopic dermatitis (AD) itch.
Major finding: A higher proportion of patients receiving abrocitinib 200 mg and 100 mg vs placebo experienced clinically meaningful itch improvement at week 2 (44.2% and 24.9% vs 5.8%), which continued through week 12 (57.3% and 42.9% vs 16.5%; both P less than .05). Mean percentage reductions in itch scores 24 hours after the first dose were greater for abrocitinib 200 mg and 100 mg vs placebo which was maintained through week 12 (−56.1 and −42.3 vs −19.5).
Study details: Findings are from a pooled analysis of 1 phase 2b (NCT02780167) and 2 phase 3 (JADE MONO-1 and JADE MONO-2) trials including 942 patients with moderate-to-severe AD who received abrocitinib 200 mg, abrocitinib 100 mg, or placebo.
Disclosures: This study was sponsored by Pfizer, Inc. Some of the authors declared receiving grants and personal fees and/or serving as consultant, speaker, advisor, and/or principal investigator for various sources including Pfizer. Six of the authors declared being employees and shareholders of Pfizer, Inc.
Source: Kim BS et al. Dermatitis. 2021 Jul 7. doi: 10.1097/DER.0000000000000770.
Key clinical point: Abrocitinib monotherapy was associated with a rapid and profound relief in atopic dermatitis (AD) itch.
Major finding: A higher proportion of patients receiving abrocitinib 200 mg and 100 mg vs placebo experienced clinically meaningful itch improvement at week 2 (44.2% and 24.9% vs 5.8%), which continued through week 12 (57.3% and 42.9% vs 16.5%; both P less than .05). Mean percentage reductions in itch scores 24 hours after the first dose were greater for abrocitinib 200 mg and 100 mg vs placebo which was maintained through week 12 (−56.1 and −42.3 vs −19.5).
Study details: Findings are from a pooled analysis of 1 phase 2b (NCT02780167) and 2 phase 3 (JADE MONO-1 and JADE MONO-2) trials including 942 patients with moderate-to-severe AD who received abrocitinib 200 mg, abrocitinib 100 mg, or placebo.
Disclosures: This study was sponsored by Pfizer, Inc. Some of the authors declared receiving grants and personal fees and/or serving as consultant, speaker, advisor, and/or principal investigator for various sources including Pfizer. Six of the authors declared being employees and shareholders of Pfizer, Inc.
Source: Kim BS et al. Dermatitis. 2021 Jul 7. doi: 10.1097/DER.0000000000000770.
Key clinical point: Abrocitinib monotherapy was associated with a rapid and profound relief in atopic dermatitis (AD) itch.
Major finding: A higher proportion of patients receiving abrocitinib 200 mg and 100 mg vs placebo experienced clinically meaningful itch improvement at week 2 (44.2% and 24.9% vs 5.8%), which continued through week 12 (57.3% and 42.9% vs 16.5%; both P less than .05). Mean percentage reductions in itch scores 24 hours after the first dose were greater for abrocitinib 200 mg and 100 mg vs placebo which was maintained through week 12 (−56.1 and −42.3 vs −19.5).
Study details: Findings are from a pooled analysis of 1 phase 2b (NCT02780167) and 2 phase 3 (JADE MONO-1 and JADE MONO-2) trials including 942 patients with moderate-to-severe AD who received abrocitinib 200 mg, abrocitinib 100 mg, or placebo.
Disclosures: This study was sponsored by Pfizer, Inc. Some of the authors declared receiving grants and personal fees and/or serving as consultant, speaker, advisor, and/or principal investigator for various sources including Pfizer. Six of the authors declared being employees and shareholders of Pfizer, Inc.
Source: Kim BS et al. Dermatitis. 2021 Jul 7. doi: 10.1097/DER.0000000000000770.